If what you said was true you would have showed "us".
More rubbish disparaging. By 'blur' you mean, speak of CYP's cleared GVHD FDA IND application in 2022, and CYP's expediated pathway knee osteoarthritis a phase III trial from the TGA from back in 2020, being discussed in the same paragraph. LMAO.
Only a simpleton without the faintest idea of the realm of discussion could confuse them as at all connected applications. Are you a simpleton? Is that what you are 'showing us'?
Perhaps I do you an injustice and you are not purposefully misrepresenting CYP. Perhaps you just genuinely get things wrong.
CYP Price at posting:
17.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)